Abi Haras-Vainstein

Modi'in Makkabbim Re'ut, M, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Journal: Blood
Published: October 14, 2025

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Journal: Blood
Published: October 14, 2025

The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses.

The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses.

Journal: Frontiers in immunology
Published: November 04, 2024

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor.

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor.

Journal: Blood advances
Published: April 07, 2023

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.

Journal: Nature medicine
Published: August 25, 2022

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 12, 2021

BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.

BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.

Journal: Cancer
Published: August 02, 2020

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.

Journal: Nature medicine
Published: July 30, 2019
Showing 1-8 of 8

Last Updated: 09/26/2026